Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.
You may also be interested in...
Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.
Panelists at US FDA advisory committee on Inspirion's RoxyBond note reservations about abuse-deterrent claims absent more real-world data on how they work; FDA's Staffa suggests agency is eager to see how well premarket work predicts postmarket experience – though the data are far from being available.
‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.